The controversial anti-dengue vaccine, Dengvaxia
The New England Journal of Medicine published an article about the negative effects of the controversial anti-dengue vaccine, Dengvaxia to those who have not contracted the disease prior to inoculation.
According to the article entitled “Impact of Dengue Serostatus on Dengue Vaccine Safety and Efficacy,” the vaccine is effective in protecting the patient from a re-occurrence of dengue. However, to those without prior dengue infection, the vaccine is not recommended as it could lead to severe dengue.
The study focused on the analysis of the dengue vaccine manufactured by Sanofi Pasteur which is Dengvaxia. This means the research study is in conformity with the recommendation of the World Health Organization (WHO) in April that Dengvaxia should not be administered to children without prior exposure to dengue.
In November 2017, Sanofi Pasteur issued a warning saying there is very high possibility of contracting severe dengue if Dengvaxia is received by individuals without prior dengue infection.
Dengvaxia has been administered to nearly 800,000 children in the Philippines under the government’s Dengue immunization program. – UNTV News & Rescue
The post Study affirms negative effects of Dengvaxia appeared first on UNTV News.